Literature DB >> 18566541

Leukemic cluster growth in culture is an independent risk factor for acute myeloid leukemia and short survival in patients with myelodysplastic syndrome.

Michael Bernimoulin1, Martin Stern, André Tichelli, Martine Jotterand, Alois Gratwohl, Catherine Nissen.   

Abstract

In patients with myelodysplastic syndrome (MDS) precursor cell cultures (colony-forming unit cells, CFU-C) can provide an insight into the growth potential of malignant myeloid cells. In a retrospective single-center study of 73 untreated MDS patients we assessed whether CFU-C growth patterns were of prognostic value in addition to established criteria. Abnormalities were classified as qualitative (i.e. leukemic cluster growth) or quantitative (i.e. strongly reduced/absent growth). Thirty-nine patients (53%) showed leukemic growth, 26 patients (36%) had strongly reduced/absent colony growth, and 12 patients showed both. In a univariate analysis the presence of leukemic growth was associated with strongly reduced survival (at 10 years 4 vs. 34%, p = 0.004), and a high incidence of transformation to AML (76 vs. 32%, p = 0.01). Multivariate analysis identified leukemic growth as a strong and independent predictor of early death (relative risk 2.12, p = 0.03) and transformation to AML (relative risk 2.63, p = 0.04). Quantitative abnormalities had no significant impact on the disease course. CFU-C assays have a significant predictive value in addition to established prognostic factors in MDS. Leukemic growth identifies a subpopulation of MDS patients with poor prognosis. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18566541     DOI: 10.1159/000140675

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  1 in total

1.  Colony-forming unit cell (CFU-C) assays at diagnosis: CFU-G/M cluster predicts overall survival in myelodysplastic syndrome patients independently of IPSS-R.

Authors:  Bing Li; Jinqin Liu; Shiqiang Qu; Robert Peter Gale; Zhen Song; Ruixian Xing; Junxia Liu; Yansong Ren; Zefeng Xu; Tiejun Qin; Yue Zhang; Liwei Fang; Hongli Zhang; Lijuan Pan; Naibo Hu; Wenyu Cai; Peihong Zhang; Gang Huang; Zhijian Xiao
Journal:  Oncotarget       Date:  2016-10-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.